natgillin/translations-raw huggingface dataset:
Træk forsigtigt indholdet af ampullen op i en steril sprøjte, påsat en 18-G kanyle. 
Gently withdraw the contents of the ampoule into a sterile syringe, mounted with an 18 gauge needle.
OPBEVARINGSBETINGELSER Opbevares ved temperaturer under 25 °C. 
STORAGE CONDITIONS Store below 25 °C.
Cellesuspension: 
Cell suspension:
B. BETINGELSER ELLER BEGRÆNSNINGER FOR MARKEDSFØRINGSTILLADELSEN VEDRØRENDE UDLEVERING OG BRUG 
CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE
Suspension og solvens til injektionsvæske, suspension. 
PHARMACEUTICAL FORM Suspension and solvent for suspension for injection.
Vaccinen er en celleassocieret levende, rekombinant kalkunherpesvirus (HVT), der udviser gD- og gIglycoproteiner over for infektiøs laryngotracheitis-virus. 
The vaccine is a cell-associated live recombinant turkey herpesvirus (HVT) expressing the gD and gI glycoproteins of infectious laryngotracheitis virus.
4.2 Terapeutiske indikationer med angivelse af dyrearter, som lægemidlet er beregnet til Til aktiv immunisering af daggamle kyllinger for at reducere mortalitet, kliniske symptomer og læsioner forårsaget af infektion med aviær infektiøs laryngotracheitis-virus (ILTV) og Marek's disease-virus (MDV). 
4.2 Indications for use, specifying the target species For active immunisation of one-day-old chicks to reduce mortality, clinical signs and lesions due to infection with avian infectious laryngotracheitis (ILT) virus and Marek's disease (MD) virus.
Fjern skyllevæsken fra ampullen med sprøjten og injicér den forsigtigt i posen med solvens. 
Remove the washing from the ampoule and inject it gently into the solvent bag.
Til aktiv immunisering af daggamle kyllinger for at reducere dødelighed, kliniske symptomer og læsioner forårsaget af infektion med aviær infektiøs laryngotracheitis-virus (ILTV) og Marek's disease-virus (MDV (smitsom hønselammelse)). 
For active immunization of one-day-old chicks to reduce mortality, clinical signs and lesions due to infection with avian infectious laryngotracheitis (ILT) virus and Marek's disease (MD) virus.
Farmakoterapeutisk gruppe: Immunologica til hønsefugle, levende virale vacciner ATCvet-kode: QI01AD. 
Pharmacotherapeutic group: immunologicals for Aves, live viral vaccines for domestic fowls.
Beholder: Opbevar beholderen med flydende kvælstof sikkert, idet den placeres opretstående i et rent, tørt rum med god ventilation, som er adskilt fra ruge-/kyllingekasser i rugeriet. 
Container: Store liquid nitrogen container securely in upright position in a clean, dry and well-ventilated room separated from the hatching/chicken room in the hatchery.
Opbevar beholderen med flydende kvælstof sikkert, idet den placeres opretstående i et rent, tørt rum med god ventilation, som er adskilt fra ruge-/kyllingekasser i rugeriet. 
Store liquid nitrogen container securely in upright position in a clean, dry and well-ventilated room separated from the hatching/chicken room in the hatchery.
Inden ampuller tages op af beholderen med flydende kvælstof skal man iklæde sig beskyttelsesudstyr bestående af handsker, lange ærmer, en ansigtsmaske og beskyttelsesbriller. 
Before withdrawing ampoules from the liquid nitrogen canister, protective equipment consisting of gloves, long sleeves and a facemask and goggles should be worn.
- 800 ml solvens i pose af polyethylen eller flerlagspose af plast. 
- 800 ml polyethylene or multilayer plastic bags of solvent.
- 400 ml solvens i pose af polyethylen eller flerlagspose af plast. 
- 400 ml polyethylene or multilayer plastic bags of solvent.
Inden ampuller tages op af beholderen med flydende kvælstof skal man iklæde sig beskyttelsesudstyr bestående af handsker, lange ærmer, ansigtsmaske og beskyttelsesbriller. 
Before withdrawing ampoules from the liquid nitrogen canister, use a personal protective equipment consisting of gloves, long sleeves and facemask and goggles.
Celleassocieret levende, rekombinant kalkunherpesvirus (stamme HTV/ILT-138) , der udviser glycoproteinerne gD og gI over for infektiøs laryngotracheitis-virus: 103.1 - 104.1 PFU1. 
Cell-associated live recombinant turkey herpesvirus (strain HVT/ILT-138), expressing the glycoproteins gD and gI of infectious laryngotracheitis virus:
DYREARTER Kyllinger 
TARGET SPECIES
Behandling med Neoclarityn reducerede også signifikant påvirkningen af søvn og daglig funktionsevne, målt ved en fire-points skala, der anvendtes for at vurdere disse parametre. 
Treatment with Neoclarityn also significantly reduced interference with sleep and daytime function, as measured by a four-point scale used to assess these variables.
Sikkerheden af desloratadin syrup-formuleringen, som indeholder samme koncentration af desloratadin som Neoclarityn oral opløsning, blev imidlertid påvist i tre pædiatriske studier. 
However, the safety of desloratadine syrup formulation, which contains the same concentration of desloratadine as Neoclarityn oral solution, was demonstrated in three paediatric trials.
Hvornår Neoclarityn skal bruges 
When Neoclarityn should be used
Hvad Neoclarityn er Neoclarityn indeholder desloratadin, som er et antihistamin. 
What Neoclarityn is Neoclarityn contains desloratadine which is an antihistamine.
Vand har ingen indflydelse på biotilgængeligheden for Neoclarityn smeltetabletter. 
Water had no effect on the bioavailability of Neoclarityn orodispersible tablets.
Da Neoclarityn oral opløsning indeholder samme koncentration af desloratadin, var et bioækvivalensstudie ikke nødvendigt, og den orale opløsning forventes at være ækvivalent med syruppen og tabletten. 
As Neoclarityn oral solution contains the same concentration of desloratadine, no bioequivalence study was required and it is expected to be equivalent to the syrup and tablet.
Virkningen af Neoclarityn smeltetablet forventes derfor at være den samme som med Neoclarityn tabletformuleringen. 
Therefore, the efficacy of Neoclarityn orodispersible tablet is expected to be the same as with the Neoclarityn tablet formulation.
Neoclarityn regulerede effektivt symptomerne i 24 timer. 
Neoclarityn effectively controlled symptoms for 24 hours.
Neoclarityn-tabletter regulerede effektivt symptomerne i 24 timer. 
Neoclarityn tablets effectively controlled symptoms for 24 hours.
I to placebokontrollerede seks-ugers studier hos patienter med kronisk idiopatisk urticaria var Neoclarityn effektivt til at lindre kløe og mindske størrelsen og antallet af kløende udslæt ved slutningen af det første doseringsinterval. 
In two placebo-controlled six week trials in patients with chronic idiopathic urticaria, Neoclarityn was effective in relieving pruritus and decreasing the size and number of hives by the end of the first dosing interval.
Hvorvidt amningen skal fortsættes eller om behandlingen med Neoclarityn skal seponeres/undlades skal vurderes ud fra afvejning af barnets fordele ved amning og kvindens fordele ved behandling. 
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Neoclarityn therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Under markedsføring af Neoclarityn er tilfælde af alvorlige allergiske reaktioner (vejrtrækningsbesvær, hiven efter vejret, kløe, kløende udslæt og hævelse) blevet rapporteret meget sjældent. 
During the marketing of Neoclarityn, cases of severe allergic reactions (difficulty in breathing, wheezing, itching, hives and swelling) have been reported very rarely.
Du skal udvise forsigtighed, hvis du tager Neoclarityn sammen med alkohol 
Use caution when taking Neoclarityn with alcohol.
Yderligere oplysninger om Neoclarityn findes på Det Europæiske Lægemiddelagenturs hjemmeside http://www.ema.europa.eu. 
Detailed information on this medicine is available on the European Medicines Agency website http://www.ema.europa.eu.
For en sikkerheds skyld bør Neoclarityn undgås under graviditet. 
As a precautionary measure, it is preferable to avoid the use of Neoclarityn during pregnancy.
Neoclarityn-tabletter indeholder lactose. 
Neoclarityn tablets contain lactose.
Hvis du har glemt at tage Neoclarityn 
If you forget to take Neoclarityn
Neoclarityn smeltetabletter indeholder aspartam Dette præparat indeholder aspartam. 
Neoclarityn orodispersible tablet contains aspartame This product contains aspartame.
Klinisk virkning og sikkerhed I et flerdosisstudie var Neoclarityn smeltetabletter veltolereret. 
Clinical efficacy and safety In a multiple dose trial, Neoclarityn orodispersible tablets were well tolerated.
1 filmovertrukket tablet 2 filmovertrukne tabletter 3 filmovertrukne tabletter 5 filmovertrukne tabletter 7 filmovertrukne tabletter 10 filmovertrukne tabletter 14 filmovertrukne tabletter 15 filmovertrukne tabletter 20 filmovertrukne tabletter 21 filmovertrukne tabletter 30 filmovertrukne tabletter 50 filmovertrukne tabletter 100 filmovertrukne tabletter 
1 film-coated tablet 2 film-coated tablets 3 film-coated tablets 5 film-coated tablets 7 film-coated tablets 10 film-coated tablets 14 film-coated tablets 15 film-coated tablets 20 film-coated tablets 21 film-coated tablets 30 film-coated tablets 50 film-coated tablets 100 film-coated tablets
Brug af anden medicin sammen med Neoclarityn Der er ingen kendte interaktioner mellem Neoclarityn og andre lægemidler. 
There are no known interactions of Neoclarityn with other medicines.
Det frarådes, at du tager Neoclarityn, hvis du er gravid, eller hvis du ammer dit spædbarn. 
Taking Neoclarityn is not recommended if you are pregnant or nursing a baby.
Virkningen af Neoclarityn-tabletter er ikke blevet tydeligt vist i studier med unge patienter mellem 12 og 17 år. 
The efficacy of Neoclarityn tablets has not been clearly demonstrated in trials with adolescent patients 12 through 17 years of age.
I kliniske studier med Neoclarityn er følgende bivirkninger blevet rapporteret som: 
In clinical studies with Neoclarityn, the following side effects were reported as:
Virkningen af Neoclarityn syrup er ikke undersøgt i pædiatriske studier med børn under 12 år. 
Efficacy of Neoclarityn syrup has not been investigated in paediatric trials in children less than 12 years of age.
I et separat studie havde grapefrugtjuice ingen indflydelse på omsætningen af desloratadin. 
In a separate study, grapefruit juice had no effect on the disposition of desloratadine.
Hvis du har glemt at tage Neoclarityn smeltetabletter Hvis du glemmer at tage din medicin til tiden, så tag den snarest muligt og vend derefter tilbage til din sædvanlige medicineringsplan. 
If you forget to take Neoclarityn orodispersible tablet If you forget to take your dose on time, take it as soon as possible and then go back to your regular dosing schedule.
Bivirkninger set med Neoclarityn 
Adverse reactions seen with Neoclarityn
Ved den anbefalede dosis blev Neoclarityn 5 mg smeltetablet fundet værende bioækvivalent med den konventionelle Neoclarityn 5 mg tabletformulering af desloratadin. 
At the recommended dose, Neoclarityn 5 mg orodispersible tablet was found to be bioequivalent to the Neoclarityn 5 mg conventional tablet formulation of desloratadine.
Brug af Neoclarityn smeltetabletter sammen med mad, drikke og alkohol Neoclarityn smeltetabletter behøver ikke at blive taget med vand eller væske. 
Neoclarityn orodispersible tablet with food, drink and alcohol Neoclarityn orodispersible tablet does not need to be taken with water or liquid.
Neoclarityn oral opløsning indeholder sorbitol 
Neoclarityn oral solution contains sorbitol
Prævalensen af denne fænotype som er dårlig til at metabolisere var højere blandt voksne negroide end voksne kaukasere (hhv. 18 % og 2 %), sikkerhedsprofilen for disse forsøgspersoner var imidlertid ikke forskellig fra profilen for den almindelige population. 
The prevalence of this poor metaboliser phenotype was greater among Black adults than Caucasian adults (18 % vs. 2 %) however the safety profile of these subjects was not different from that of the general population.
Neoclarityn oral opløsning indeholder sorbitol. 
Neoclarityn oral solution contains sorbitol.
Herudover kan Neoclarityn smeltetabletter tages med eller uden mad. 
Additionally, Neoclarityn orodispersible tablet may be taken with or without a meal.
I et éndosis overkrydsningsstudie af desloratadin blev tablet- og syrup-formuleringerne fundet at være bioækvivalente. 
In a single dose, crossover study of desloratadine, the tablet and the syrup formulations were found to be bioequivalent.
I enkeltdosis overkrydsningsstudier af Neoclarityn 5 mg smeltetablet over for konventionelle Neoclarityn 5 mg tabletter var formuleringerne bioækvivalente. 
In single-dose crossover studies of Neoclarityn 5 mg orodispersible tablets with Neoclarityn 5 mg conventional tablets, the formulations were bioequivalent.
Neoclarityn oral opløsning leveres i flasker med 30, 50, 60, 100, 120, 150, 225 og 300 ml i type III ravgule glasflasker lukket med et børnesikkert polypropylenskruelåg med en indsats af multi-ply polyethylen. 
Neoclarityn oral solution, is supplied in 30, 50, 60, 100, 120, 150, 225 and 300 ml size Type III amber glass bottles closed with a plastic child resistant (C/R) screw closure having a multi-ply polyethylenefaced liner.
Den anbefalede dosis Neoclarityn er to 2,5 mg smeltetabletter lagt i munden en gang dagligt. 
The recommended dose of Neoclarityn is two 2.5 mg orodispersible tablets placed in the mouth once a day.
Hvis du har taget for meget Neoclarityn oral opløsning Tag udelukkende Neoclarityn oral opløsning således, som det er ordineret til dig. 
If you take more Neoclarityn oral solution than you should Take Neoclarityn oral solution only as it is prescribed for you.
Voksne Efter markedsføring af Neoclarityn er følgende bivirkninger blevet rapporteret: 
Adults During the marketing of Neoclarityn, the following side effects were reported as:
Efter markedsføring af Neoclarityn er følgende bivirkninger blevet rapporteret: 
During the marketing of Neoclarityn, the following side effects were reported as:
Neoclarityn 2,5 mg smeltetabletter er lys rød, plettet og rund med ”K” trykt på den ene side. 
Neoclarityn 2.5 mg orodispersible tablet is light red, speckled, and round with “K” branded on one side.
Neoclarityn var effektivt til at lindre generne ved sæsonbetinget allergisk rhinitis, vist ved den totale score i rhino-konjunktivitis livskvalitetsspørgeskemaet. 
Neoclarityn was effective in alleviating the burden of seasonal allergic rhinitis as shown by the total score of the rhino-conjunctivitis quality of life questionnaire.
Dette lægemiddel indeholder 1,4 mg phenylalanin per 2,5 mg Neoclarityn smeltetablet. 
This product contains 1.4 mg of phenylalanine per 2.5 mg dose of Neoclarityn orodispersible tablet.
I et klinisk farmakologisk studie forstærkede Neoclarityn-tabletter indtaget sammen med alkohol ikke alkohols præstationshæmmende virkninger (se pkt. 
In a clinical pharmacology trial, Neoclarityn tablets taken concomitantly with alcohol did not potentiate the performance impairing effects of alcohol (see section 5.1).
Navn og adresse på den fremstiller, der er ansvarlig for batchfrigivelse af filmovertrukne tabletter 
Name and address of the manufacturer responsible for batch release for film coated tablets
Neoclarityn 5 mg smeltetabletter er lys rød, plettet og rund med ”A” trykt på den ene side. 
Neoclarityn 5 mg orodispersible tablet is light red, speckled, and round with “A” branded on one side.
Tag ikke lægemidlet, hvis du bemærker ændringer i udseendet af Neoclarityn smeltetabletter. 
Do not use this medicine if you notice any change in the appearance of Neoclarityn orodispersible tablet.
Dette lægemiddel indeholder 2,9 mg phenylalanin per 5 mg Neoclarityn smeltetablet. 
This product contains 2.9 mg of phenylalanine per 5 mg dose of Neoclarityn orodispersible tablet.
Børn i alderen 1 til 5 år: 2,5 ml (1,25 mg) Neoclarityn oral opløsning en gang daglig. 
Children 1 through 5 years of age: 2.5 ml (1.25 mg) Neoclarityn oral solution once a day.
Neoclarityn-tabletter lindrede effektivt generne ved sæsonbetonet allergisk rhinitis, vist ved den totale score i rhino-konjunktivitis livskvalitetsspørgeskemaet. 
Neoclarityn tablets were effective in alleviating the burden of seasonal allergic rhinitis as shown by the total score of the rhino-conjunctivitis quality of life questionnaire.
Hos de fleste børn og voksne var bivirkningerne i kliniske studier med Neoclarityn nogenlunde de samme som ved en placeboopløsning eller placebotablet. 
In clinical studies in most children and adults, side effects with Neoclarityn were about the same as with a dummy solution or tablet.
Voksne og unge (i alderen 12 år og derover) Den anbefalede dosis af Neoclarityn er en tablet en gang dagligt. 
Adults and adolescents (12 years of age and over) The recommended dose of Neoclarityn is one tablet once a day.
Kontakt lægen, apoteket eller sundhedspersonalet, før du tager Neoclarityn. 
Talk to your doctor, pharmacist or nurse before taking Neoclarityn: - if you have poor kidney function.
Brug af Neoclarityn sammen med mad, drikke og alkohol Neoclarityn kan tages med eller uden mad. 
Neoclarityn with food, drink and alcohol Neoclarityn may be taken with or without a meal.
Virkningen af Neoclarityn oral opløsning er ikke vurderet i særlige studier hos børn. 
Efficacy of Neoclarityn oral solution has not been investigated in separate paediatric trials.
Børn i alderen 6 til 11 år: den anbefalede dosis Neoclarityn er en 2,5 mg smeltetablet lagt i munden en gang dagligt. 
Children 6 to 11 years of age: the recommended dose of Neoclarityn is one 2.5 mg orodispersible tablet placed in mouth once a day.
Neoclarityn indeholder lactose 
Neoclarityn contains lactose
Det skal du vide, før du begynder at tage Neoclarityn 
What you need to know before you take Neoclarityn
Brug af Neoclarityn oral opløsning sammen med mad, drikke og alkohol Neoclarityn kan tages med eller uden mad. 
Neoclarityn oral solution with food, drink and alcohol Neoclarityn may be taken with or without a meal.
Neoclarityn er et lægemiddel mod allergi, som ikke gør dig døsig. 
Neoclarityn is an antiallergy medicine that does not make you drowsy.
Neoclarityn leveres i blistre af formstøbt blisterfilm med folielåg. 
Neoclarityn is supplied in blisters comprised of laminate blister film with foil lidding.
Neoclarityn indeholder: 
What Neoclarityn contains
Det skal du vide, før du begynder at tage Neoclarityn oral opløsning 
What you need to know before you take Neoclarityn oral solution
Med hensyn til varigheden af behandlingen, vil din læge bestemme hvilken type allergisk snue, du lider af, og vil fastsætte, hvor længe du skal tage Neoclarityn oral opløsning. 
Regarding the duration of treatment, your physician will determine the type of allergic rhinitis you are suffering from and will determine for how long you should take Neoclarityn oral solution.
Med hensyn til varigheden af behandlingen, vil din læge bestemme hvilken type allergisk snue, du lider af, og vil fastsætte, hvor længe du skal tage Neoclarityn. 
Regarding the duration of treatment, your physician will determine the type of allergic rhinitis you are suffering from and will determine for how long you should take Neoclarityn.
Neoclarityn 5 mg filmovertrukne tabletter er pakket i enkeltdosisblisterpakninger med 1, 2, 3, 5, 7, 10, 14, 15, 20, 21, 30, 50 eller 100 tabletter. 
Neoclarityn 5 mg film-coated tablets are packed in blisters in packs of 1, 2, 3, 5, 7, 10, 14, 15, 20, 21, 30, 50 or 100 tablets.
Børn i alderen 6 til 11 år: 5 ml (2,5 mg) Neoclarityn oral opløsning en gang daglig. 
Children 6 through 11 years of age: 5 ml (2.5 mg) Neoclarityn oral solution once a day.
Med hensyn til varigheden af behandlingen, vil din læge bestemme hvilken type allergisk snue, du lider af, og vil fastsætte, hvor længe du skal tage Neoclarityn smeltetabletter. 
Regarding the duration of treatment, your physician will determine the type of allergic rhinitis you are suffering from and will determine for how long you should take Neoclarityn orodispersible tablets.
Ved den anbefalede dosis i kliniske studier omfattende voksne og unge ved en række indikationer omfattende allergisk rhinitis og kronisk idiopatisk urticaria, blev bivirkninger med Neoclarityn rapporteret hos 3 % flere patienter end hos dem, der behandledes med placebo. 
At the recommended dose, in clinical trials involving adults and adolescents in a range of indications including allergic rhinitis and chronic idiopathic urticaria, undesirable effects with Neoclarityn were reported in 3 % of patients in excess of those treated with placebo.
Sikkerhed og virkning af Neoclarityn 0,5 mg/ml oral opløsning hos børn under 1 år er ikke klarlagt. 
The safety and efficacy of Neoclarityn 0.5 mg/ml oral solution in children below the age of 1 year have not been established.
Vurderet på baggrund af kliniske studier påvirker Neoclarityn ikke eller kun i ubetydelig grad evnen til at føre motorkøretøj og betjene maskiner. 
Neoclarityn has no or negligible influence on the ability to drive and use machines based on clinical trials.
Lægen bør være opmærksom på, at de fleste tilfælde af rhinitis hos børn under 2 år skyldes infektioner (se pkt. 
The prescriber should be aware that most cases of rhinitis below 2 years of age are of infectious origin (see section 4.4) and there are no data supporting the treatment of infectious rhinitis with Neoclarityn.
I forbindelse med dosisjusteringsstudierne hos børn underbygger de farmakokinetiske data for Neoclarityn smeltetabletter imidlertid brugen af 2,5 mg dosen til børn i alderen 6 til 11 år. 
Neoclarityn 2.5 mg tablets has not been evaluated in paediatric patients however in conjunction with the dose finding studies in paediatrics, the pharmacokinetics data for Neoclarityn orodispersible tablets supports the use of the 2.5 mg dose in paediatric patients 6 to 11 years of age.
Neoclarityn-tabletter, givet i en enkelt daglig dosis på 7,5 mg til voksne og unge, påvirkede ikke den psykomotoriske præstationsevne i kliniske studier. 
Neoclarityn tablets given at a single daily dose of 7.5 mg to adults and adolescents did not affect psychomotor performance in clinical trials.
Sådan skal du tage Neoclarityn 
How to take Neoclarityn
Det skal du vide, før du begynder at tage Neoclarityn smeltetabletter 
What you need to know before you take Neoclarityn orodispersible tablet
Neoclarityn oral opløsning indeholder: 
What Neoclarityn oral solution contains
Neoclarityn 0,5 mg/ml oral opløsning 
Neoclarityn 0.5 mg/ml oral solution
Neoclarityn oral opløsning er et lægemiddel mod allergi, som ikke gør dig døsig. 
Neoclarityn oral solution is an antiallergy medicine that does not make you drowsy.
Sådan skal du tage Neoclarityn oral opløsning 
How to take Neoclarityn oral solution
Neoclarityn bør anvendes med forsigtighed til patienter med svær nyreinsufficiens (se pkt. 
In the case of severe renal insufficiency, Neoclarityn should be used with caution (see section 5.2).
Neoclarityn smeltetabletter er et lægemiddel mod allergi, som ikke gør dig døsig. 
Neoclarityn orodispersible tablet is an antiallergy medicine that does not make you drowsy.
Neoclarityn, givet i en enkelt daglig dosis på 7,5 mg, påvirkede ikke den psykomotoriske præstationsevne i kliniske studier. 
Neoclarityn given at a single daily dose of 7.5 mg did not affect psychomotor performance in clinical trials.
I kliniske studier ved en række indikationer omfattende allergisk rhinitis og kronisk idiopatisk urticaria, ved den anbefalede dosis på 5 mg daglig, blev bivirkninger med Neoclarityn-tabletter rapporteret hos 3 % flere patienter end hos dem, der behandledes med placebo. 
In clinical trials in a range of indications including allergic rhinitis and chronic idiopathic urticaria, at the recommended dose of 5 mg daily, undesirable effects with Neoclarityn tablets were reported in 3 % of patients in excess of those treated with placebo.
Neoclarityn-tabletter, givet i en enkelt daglig dosis på 7,5 mg, påvirkede ikke den psykomotoriske præstationsevne i kliniske studier. 
Neoclarityn tablets given at a single daily dose of 7.5 mg did not affect psychomotor performance in clinical trials.